Coya Therapeutics (COYA) AGM 2026 summary

Opening remarks and agenda

• Meeting opened with a welcome, introductions of board members, legal counsel, and independent inspector of elections.

• Attendees were informed about the Q&A session and meeting procedures.

• Voting would be limited to two proposals as no additional shareholder proposals were received.

Board and executive committee updates

• Board nominated Wilbur Ross and Dieter Weinand for re-election as directors until the 2029 annual meeting.

• Weaver and Tidwell, L.L.P. was proposed for ratification as independent registered public accounting firm for fiscal year 2026.

Financial performance review

• Reported cash balance of $50.7 million as of March 31, 2026, with guidance that funds will last into the second half of 2027.

• Strategic partnership with Dr. Reddy's Laboratories provided non-dilutive capital and potential for up to $650 million in sales milestones and mid-teen royalties upon commercialization.